• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aldeyra Therapeu (NQ: ALDX )

    5.370 -0.070 (-1.29%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 200,987
    Open 5.360
    Bid (Size) 5.100 (2)
    Ask (Size) 5.450 (5)
    Prev. Close 5.440
    Today's Range 5.250 - 5.420
    52wk Range 1.460 - 7.810
    Shares Outstanding 58,576,350
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%
    Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potential 2024 NDA resubmission. 
    Via Benzinga
    Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
    From Aldeyra Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +51.69%
    +51.69%
    1 Month
    +36.29%
    +36.29%
    3 Month
    +41.69%
    +41.69%
    6 Month
    +46.72%
    +46.72%
    1 Year
    -29.16%
    -29.16%

    More News

    Read More
    Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Aldeyra Therapeutics to Host Investor Roundtable Q&A
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024
    Via InvestorPlace
    Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
    Via Benzinga
    Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    3 Stocks at the Forefront of Personalized Medicine Trend
    Via InvestorPlace
    FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study
    Via Benzinga
    Exposures Product Safety
    Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
    From Aldeyra Therapeutics, Inc.
    Via Business Wire
    Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.